Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 3Sarcoma 3Head & Neck 3Gastrointestinal 2Dermatologic 2Plasma cell 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Endocrine 1CNS 1Breast 1

Conditions

Paraproteinemias 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 262Lenalidomide 157daratumumab 135Bortezomib 113pomalidomide 89Calcium Dobesilate 86Cyclophosphamide 84carfilzomib 76Specimen Handling 46isatuximab 44fludarabine 43Biopsy 43belantamab mafodotin 41Magnetic Resonance Spectroscopy 38dexamethasone acetate 34dexamethasone 21-phosphate 34auricularum 33Melphalan 32talquetamab 29ixazomib 27iberdomide 27fludarabine phosphate 24selinexor 22elotuzumab 21Whole-Body Irradiation 17X-Rays 15venetoclax 14Mycophenolic Acid 13tocilizumab 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tissue Banks × Plasma cell × 1 year × Clear all
NCT01408225 2026-03-23

B-SCR-MM

Ohio State University Comprehensive Cancer Center

Recruiting
5,000 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡